Prostate MRI Screening Standards and Test Performance

Key Takeaways

• Across six studies involving 1,919 participants, 1,426 underwent upfront screening MRI, with pooled estimates for biopsy referral, clinically significant cancer detection, and positive predictive value.
• If MRI was used for screening, candidates were men aged 50 to 70 years with life expectancy over 10 years, or Black men from age 45. MRI followed PSA testing, but no consensus emerged on the threshold.
• The protocol centered on non-contrast T2-weighted and diffusion-weighted imaging, a 15-minute acquisition cap, stage-gated reporting, and quality requirements in accredited centers.

An international PRISM consensus paired standardized prostate MRI screening guidance with pooled evidence showing a 19.2% biopsy recommendation rate after upfront MRI. The JAMA Oncology Special Communication outlined MRI screening candidates, acquisition methods, interpretation rules, and program standards within a single framework. It placed MRI after PSA testing and described use of abbreviated protocols in accredited settings. Together, the pooled findings provided the performance backdrop for standardized prostate MRI screening.

A systematic review and meta-analysis of randomized clinical trials and prospective cohort studies evaluating MRI for screening informed the recommendations. Searches covered PubMed, CENTRAL, Scopus, Web of Science, and ClinicalTrials.gov, with citation searching and expert consultation performed in September 2024. The six included studies enrolled 1,919 participants, 1,426 of whom underwent upfront screening MRI, and most used 3.0-T non-contrast-enhanced MRI. A RAND/UCLA Appropriateness Method consensus exercise then involved 21 experts from 6 countries, including 8 urologists, 11 radiologists, and 2 pathologists, with agreement on 235 of 323 statements. Those pooled screening findings informed the consensus recommendations.

Across the pooled studies, the biopsy recommendation rate was 19.2% with a 95% CI of 11.7% to 26.7%. Detection of grade group 2 or higher prostate cancer was 6.0%, with a 95% CI of 3.1% to 9.0%. Grade group 1 cancer detection was 1.4%, with a 95% CI of 0.7% to 2.2%. The positive predictive value for grade group 2 or higher disease was 36.3%, with a 95% CI of 21.1% to 51.4%. These pooled results provided the performance backdrop for the screening standards.

If MRI was used in screening, the panel described candidates as men with estimated life expectancy greater than 10 years who were aged 50 to 70 years. For Black men, the age range began at 45 years. Screening MRI was placed after a PSA test, but the panel did not reach consensus on the optimal PSA threshold. Repeat screening was described as risk stratified according to patient characteristics. The screening pathway was therefore risk stratified rather than based on a single PSA cutoff.

For acquisition, non-contrast-enhanced MRI using only T2-weighted and diffusion-weighted imaging was considered appropriate, with a maximum acceptable acquisition time of 15 minutes. Interpretation used a stage-gated 2-step approach, with all sequences revealed only if a concordant focal lesion appeared on axial T2-weighted and high b-value diffusion imaging. Screening MRI was also limited to accredited centers with radiologists meeting minimum reporting requirements and quality standards. The investigators said the standards provide expert guidance for screening trials and future programs, while uncertainty remains about MRI use in population-level screening.